Shuxuening injection is a multi-target neuroprotective agent, it is expected to play a neuroprotective role on the basis of intravenous thrombolysis therapy. The primary purpose of this multicenter, randomized, double-blind, placebo-parallel controlled trial is to evaluate the efficacy and safety of Shuxuening injection in the treatment with intravenous thrombolysis in patients with ischemic stroke.
Age 18 or older;
Diagnosed with acute ischemic stroke;
Within 6 hours of onset;
Having received or plan to undergo intravenous thrombolytic therapy;
mRS score greater than 1 point before the onset;
Receiving neuroprotective agents, such as edaravone, edaravone dextrocamphorol, butylphthalein, etc. after the onset;
Bleeding or other pathological brain disorders, such as vascular malformations, tumors, abscesses, or other common non-ischemic brain diseases (such as multiple sclerosis), detected by CT/MRI;
History of clotting disorders, systemic bleeding, thrombocytopenia, or neutropenia;
Beijing Tiantan Hospital
Lead sponsor